In summary, blocking the IL-1R1 signaling pathway in hepatocytes not only improves the MASLD phenotype and insulin resistance, as previously demonstrated but also significantly slows hepatocarcinogenesis in the context of hepatic steatosis. The gene discussed is IL1R1; the disease is fatty liver disease.